These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 3948454)

  • 1. Age-associated changes in ceftriaxone pharmacokinetics.
    Hayton WL; Stoeckel K
    Clin Pharmacokinet; 1986; 11(1):76-86. PubMed ID: 3948454
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Single-dose ceftriaxone kinetics in the newborn.
    Schaad UB; Hayton WL; Stoeckel K
    Clin Pharmacol Ther; 1985 May; 37(5):522-8. PubMed ID: 3987175
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Protein binding characteristics and pharmacokinetics of ceftriaxone in intensive care unit patients.
    Schleibinger M; Steinbach CL; Töpper C; Kratzer A; Liebchen U; Kees F; Salzberger B; Kees MG
    Br J Clin Pharmacol; 2015 Sep; 80(3):525-33. PubMed ID: 25808018
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetic profile of ceftriaxone in man.
    Patel IH; Kaplan SA
    Am J Med; 1984 Oct; 77(4C):17-25. PubMed ID: 6093513
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetics and safety of ceftriaxone in the neonate.
    Mulhall A; de Louvois J; James J
    Eur J Pediatr; 1985 Nov; 144(4):379-82. PubMed ID: 4076254
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Explaining the poor bacteriologic eradication rate of single-dose ceftriaxone in group a streptococcal tonsillopharyngitis: a reverse engineering solution using pharmacodynamic modeling.
    Blumer JL; Reed MD; Kaplan EL; Drusano GL
    Pediatrics; 2005 Oct; 116(4):927-32. PubMed ID: 16199703
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Pharmacokinetic and clinical studies of ceftriaxone in neonates].
    Nishimura T; Takashima T; Tabuki K; Takagi M
    Jpn J Antibiot; 1988 Feb; 41(2):144-50. PubMed ID: 3373736
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Pharmacokinetic and clinical evaluations on ceftriaxone in neonates and premature infants].
    Shiro H; Kusumoto Y; Satoh Y; Oikawa T; Osano M
    Jpn J Antibiot; 1988 Mar; 41(3):236-43. PubMed ID: 3404644
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetics of ceftriaxone in liver-transplant recipients.
    Toth A; Abdallah HY; Venkataramanan R; Teperman L; Halsf G; Rabinovitch M; Burckart GJ; Starzl TE
    J Clin Pharmacol; 1991 Aug; 31(8):722-8. PubMed ID: 1880231
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Biliary precipitation during ceftriaxone therapy: frequency and risk factors.
    Soysal A; Eraşov K; Akpinar I; Bakir M
    Turk J Pediatr; 2007; 49(4):404-7. PubMed ID: 18246742
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Variability of ceftriaxone pharmacokinetics in hospitalized patients with severe infections.
    Joos B; Luethy R; Muehlen E; Siegenthaler W
    Am J Med; 1984 Oct; 77(4C):59-62. PubMed ID: 6093521
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Pharmacokinetic and clinical evaluation of ceftriaxone in neonates and premature infants].
    Toyonaga Y; Sugita M; Hori M
    Jpn J Antibiot; 1988 Mar; 41(3):244-61. PubMed ID: 3404645
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of probenecid on the elimination and protein binding of ceftriaxone.
    Stoeckel K; Trueb V; Dubach UC; McNamara PJ
    Eur J Clin Pharmacol; 1988; 34(2):151-6. PubMed ID: 3383987
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Pharmacokinetic and clinical evaluations of ceftriaxone in neonates and premature infants].
    Motohiro T; Oda K; Aramaki M; Tanaka K; Kawakami A; Shimada Y; Koga T; Tomita S; Sakata Y; Fujimoto T
    Jpn J Antibiot; 1988 Mar; 41(3):276-305. PubMed ID: 3404647
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prediction of drug disposition in infants and children by means of physiologically based pharmacokinetic (PBPK) modelling: theophylline and midazolam as model drugs.
    Björkman S
    Br J Clin Pharmacol; 2005 Jun; 59(6):691-704. PubMed ID: 15948934
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Age differences in trimethoprim pharmacokinetics: need for revised dosing in children?
    Hoppu K
    Clin Pharmacol Ther; 1987 Mar; 41(3):336-43. PubMed ID: 3816021
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Pharmacokinetics of ceftriaxone in the first three month of life].
    Rondanelli R; Regazzi MB; Stronati M; Calvi M; Lombardi G; Rondini G
    Pediatr Med Chir; 1992; 14(1):55-9. PubMed ID: 1579518
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Pharmacokinetics and clinical evaluation of ceftriaxone in neonates].
    Fujii R; Hashira S; Sakata H; Inyaku F; Fujita K; Maruyama S; Yoshioka H; Nakazawa S; Satoh H; Narita A
    Jpn J Antibiot; 1988 Sep; 41(9):1237-50. PubMed ID: 3071615
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Evaluation of the pharmacokinetics of ceftriaxone in neonates].
    Sunakawa K; Sato Y
    Jpn J Antibiot; 1988 Feb; 41(2):128-32. PubMed ID: 3373735
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Biliary excretion and pharmacokinetics of ceftriaxone after cholecystectomy.
    Hayton WL; Schandlik R; Stoeckel K
    Eur J Clin Pharmacol; 1986; 30(4):445-51. PubMed ID: 3743620
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.